Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 357: A Randomized Controlled Multicenter Phase II Trial of Subcutaneous Interleukin-2 (scIL-2) Therapy in HIV-Infected Patients with CD4 Counts 200-500 cells/µL

February 2, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

This study, conducted by Davey and colleagues, was a randomized trial comparing treatment with subcutaneous (injected under the skin) interleukin-2 (IL-2) plus stable antiretroviral therapy (ARV) versus ARV therapy alone in 82 patients with baseline T-cell counts of 200-500 cells. The mean T-cell count was about 345, and the mean viral load was 3.1 log using the bDNA test. Thirty-nine patients were on the IL-2 arm, and 43 were on antiretroviral therapy alone. IL-2 recipients received 5-day courses every 8 weeks for 6 cycles at a starting dose of 7.5 MIU twice-a-day, decreased as needed for toxicity. Protease inhibitor use was between 80-90% on each arm. Results were as follows:


IL-2 plus ARV Baseline One Year
Mean CD4 Count (% increase): 355 739 (112% increase)
% pts., bDNA<500 copies/ml: 59% 68%
% pts., bDNA<50 copies/ml: 40% 67%

ARV alone Baseline One Year
Mean CD4 Count (% increase): 341 405 (18% increase)
% pts., bDNA<500 copies/ml: 44% 46%
% pts., bDNA<50 copies/ml: 31% 36%


The study investigators concluded that combination antiretroviral treatment with intermittent therapy with IL-2 led to a greater increase in CD4 cells, and a trend towards lower viral loads, than combination antiretroviral therapy alone.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: A Randomized Controlled Multicenter Phase II Trial of Subcutaneous Interleukin-2 (scIL-2) Therapy in HIV-Infected Patients with CD4 Counts 200-500 cells/µL
Authored by: R. Davey, R. Murphy, F. Graziano, S. Boswell, A. Pavia, M. Cancio, J. Nadler, D. Sahner, A-M. Duliege, W. Capra, C. Lane, and J. Kahn

See Also
Trial Results



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement